218 related articles for article (PubMed ID: 15681435)
1. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
Pfeiffer JK; Kirkegaard K
J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
[TBL] [Abstract][Full Text] [Related]
5. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
[TBL] [Abstract][Full Text] [Related]
6. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
[TBL] [Abstract][Full Text] [Related]
7. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.
Panigrahi R; Hazari S; Chandra S; Chandra PK; Datta S; Kurt R; Cameron CE; Huang Z; Zhang H; Garry RF; Balart LA; Dash S
PLoS One; 2013; 8(8):e72791. PubMed ID: 24009705
[TBL] [Abstract][Full Text] [Related]
8. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
Yon C; Viswanathan P; Rossignol JF; Korba B
Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
[TBL] [Abstract][Full Text] [Related]
11. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Mori K; Hiraoka O; Ikeda M; Ariumi Y; Hiramoto A; Wataya Y; Kato N
Hepatology; 2013 Oct; 58(4):1236-44. PubMed ID: 23532970
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
[TBL] [Abstract][Full Text] [Related]
13. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.
Hmwe SS; Aizaki H; Date T; Murakami K; Ishii K; Miyamura T; Koike K; Wakita T; Suzuki T
Antiviral Res; 2010 Mar; 85(3):520-4. PubMed ID: 20043953
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
15. Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.
Satoh S; Mori K; Ueda Y; Sejima H; Dansako H; Ikeda M; Kato N
PLoS One; 2015; 10(2):e0118313. PubMed ID: 25699517
[TBL] [Abstract][Full Text] [Related]
16. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
[TBL] [Abstract][Full Text] [Related]
17. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
[TBL] [Abstract][Full Text] [Related]
18. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Zhou S; Liu R; Baroudy BM; Malcolm BA; Reyes GR
Virology; 2003 Jun; 310(2):333-42. PubMed ID: 12781720
[TBL] [Abstract][Full Text] [Related]
19. Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.
Mejer N; Fahnøe U; Galli A; Ramirez S; Benfield T; Bukh J
J Gen Virol; 2018 Aug; 99(8):1066-1077. PubMed ID: 29927371
[TBL] [Abstract][Full Text] [Related]
20. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
Delang L; Scheers E; Grabner M; Verpaalen B; Helsen N; Vanstreels E; Daelemans D; Verfaillie C; Neyts J
Biochem Pharmacol; 2015 Aug; 96(3):190-201. PubMed ID: 26070251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
